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Introduction
Sustained alterations of blood pressure require resetting
of renal mechanisms maintaining salt–water balance
(1). The latter is critically dependent on sodium resorp-
tion in the distal tubule of the nephron, which is regu-
lated by mineralocorticoid hormones (principally aldos-
terone). Indeed, most human monogenic hypertensive
and hypotensive syndromes reflect mutations in genes
that determine electrolyte transport in the distal por-
tion of the nephron, either directly (2, 3) or through
alterations in mineralocorticoid- or glucocorticoid-sig-
naling pathways (4, 5).
Although physiological glucocorticoids (corticos-
terone in rats and mice, cortisol in humans) bind to
purified mineralocorticoid receptors (MR) with affini-
ties similar to aldosterone in vitro (6), in vivo MR are
selectively activated by aldosterone. This selectivity is
produced by 11b -hydroxysteroid dehydrogenase type 2
(11 b -HSD2), which catalyzes the rapid metabolism of
glucocorticoids to inert 11-keto forms (11-dehydro-
corticosterone, cortisone) (7). In the syndrome of
apparent mineralocorticoid excess (SAME) (8), defi-
ciency of renal 11 b -HSD2 allows physiological gluco-
corticoids (cortisol, corticosterone) to illicitly activate
MR in the distal tubule, producing sodium retention,
severe hypertension, and hypokalemia (7, 9, 10). How-
ever, the disorder is usually incompletely corrected by
suppression of cortisol, suggesting that irreversible
changes also occur, possibly in the kidney (11). To
examine the pathophysiological basis for this critical
hypertensive condition further, we produced mice with
targeted disruption of the 11b -HSD2 gene.
Methods
Construction of the replacement vector and gene targeting. Two over-
lapping genomic fragments, encompassing 10.5 kb of the 5 ¢
region, the complete 11 b -HSD2 gene, and 9 kb of the 3 ¢ down-
stream region, were cloned from a 129 Sv library in the l PS vec-
tor (12). Sequencing of all five exons showed a complete match
with mouse 11 b -HSD2 cDNA (13). A replacement vector was
constructed in pBS-b KnpA, containing the neomycin resistance
gene flanked by the human b -actin promoter and a SV40
polyadenylation signal sequence. A 5-kb EcoRI–BamHI frag-
ment placed immediately downstream of exon 5 was used as a
3 ¢ homology arm. The 2.7-kb SpeI–XbaI fragment from intron
A (5¢ arm of homology) was subcloned into the SpeI site of pBS-
b KnpA, so that the 3 ¢ XbaI site was not recreated after ligation.
Replacement vector linearized with SpeI and SalI was electro-
porated into embryonic stem (ES) cells (line E-14), and G418-
resistant clones were selected as described (14). Two hundred
fifty neomycin-resistant clones were analyzed by Southern blot-
ting, using XbaI analytical restriction digestion and hybridiza-
tion with a 0.8-kb XbaI-SpeI 5¢ external probe. Clones with spe-
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Deficiency of 11 b -hydroxysteroid dehydrogenase type 2 (11 b -HSD2) in humans leads to the syndrome
of apparent mineralocorticoid excess (SAME), in which cortisol illicitly occupies mineralocorticoid
receptors, causing sodium retention, hypokalemia, and hypertension. However, the disorder is usually
incompletely corrected by suppression of cortisol, suggesting additional and irreversible changes, per-
haps in the kidney. To examine this further, we produced mice with targeted disruption of the 11b -
HSD2 gene. Homozygous mutant mice (11 b -HSD2–/–) appear normal at birth, but ~ 50% show motor
weakness and die within 48 hours. Both male and female survivors are fertile but exhibit hypokalemia,
hypotonic polyuria, and apparent mineralocorticoid activity of corticosterone. Young adult 11 b -HSD2–/–
mice are markedly hypertensive, with a mean arterial blood pressure of 146 ± 2 mmHg, compared with
121 ± 2 mmHg in wild-type controls and 114 ± 4 mmHg in heterozygotes. The epithelium of the distal
tubule of the nephron shows striking hypertrophy and hyperplasia. These histological changes do not
readily reverse with mineralocorticoid receptor antagonism in adulthood. Thus, 11b -HSD2–/– mice
demonstrate the major features of SAME, providing a unique rodent model to study the molecular
mechanisms of kidney resetting leading to hypertension.
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cific recombination events were selected, and recombination at
the 3¢ end was confirmed by restriction digestion with SspI and
NotI and subsequent hybridization with the SspI–BamHI 3 ¢
external probe (not shown). Cells from four targeted ES cell
clones were injected into C57BL/6 blastocysts and transferred
into C57BL/6 · CBA foster mothers. Chimeras were bred to
MF1 females and the progeny genotyped by Southern blot
analysis of DNA digested with BamHI and SacI. Northern blot
analysis was performed as described (15).
Assays of 11 b -HSD activities. Homogenates from placentas at
embryonic day 18.5 (E18.5) were assayed for 11 b -HSD2, a
nicotinamide adenine dinucleotide (NAD)–dependent exclu-
sive 11 b -dehydrogenase, and for the lower-affinity 11 b -HSD1
isozyme, which, in vitro, is a bidirectional reduced nicotinamide
adenine dinuc 11b -HSD2 bioassays were carried out using pla-
cental tissue homogenates (0.25 mg protein/ml) incubated at
37°C with 400 m M NAD and 12 nM [3H]corticosterone (16).
11b -HSD1 was assayed in the reductase direction using 400 m M
NADPH and 12 nM [3H]-11-dehydrocorticosterone. Steroids
were extracted and quantified by HPLC (17).
Plasma renin activity was measured using the established
assay (18). Aldosterone levels were measured by using a
radioimmunoassay kit (Diagnostic Products Corp., Los Ange-
les, California, USA)
Mineralocorticoid actions of glucocorticoids in vivo. Adult male
wild-type and 11b -HSD2–null mice were injected with vehicle
(10% ethanol/saline) subcutaneously for 3 days, followed by
dexamethasone (100 m g/kg) to suppress endogenous corticos-
terone for 3 days, and finally dexamethasone (100 m g/kg) and
replacement corticosterone (10 mg/kg) for 3 days. Urine was
collected in metabolism cages for 24 h beginning 4 h after the
start of each treatment, and electrolytes were measured by auto-
matic analyzer. Basal 24-h urine collections and blood samples
from chronically cannulated animals were also obtained for
electrolyte estimations.
Blood pressure measurement. Blood pressures were measured in
3-month-old chronically cannulated, conscious males and
females as described previously (19). Microrenathane catheters
(Braintree Scientific Inc., Braintree, Massachusetts, USA) were
microsurgically implanted into the abdominal aorta. Blood
pressures were recorded directly from conscious, freely moving
mice for 10-min periods between 10 and 11am on 3–5 consec-
utive days from 48 h after the operations.
Histological preparations. Kidneys were fixed in 10% buffered
formalin and embedded in paraffin wax, and multiple adjacent
4- m m sections were cut and mounted on glass slides. After
dehydration, the sections were stained with hematoxylin and
eosin, periodic acid-Schiff, and Martius scarlet blue. Sections
were examined by an experienced pathologist (S. Fleming),
who was blinded to the genotype. Glomeruli and tubule seg-
ments were identified by positional and morphological crite-
ria, as described previously (20), because immunocytochem-
istry-based identification of tubule types is unreliable in
circumstances of tubule hypertrophy and hyperplasia (21, 22).
Individual distal tubule diameters were measured by image
analysis using a Zeiss laser scanning microscope (14). Twenty
tubule diameters were measured in each of three –/– and wild-
type animals at 3 months of age.
Tissue for electron microscopy was immersion-fixed as 1-mm
cubes in 4% glutaraldehyde in cacodylate buffer. The tissue
blocks were postfixed in osmium tetroxide, washed in cacody-
late buffer, and dehydrated through graded alcohols. Blocks
were embedded in araldite resin. Ultra-thin sections were cut,
mounted on copper grids, and stained with uranyl acetate and
lead citrate. They were examined on a Phillips CM 12 trans-
mission electron microscope.
684 The Journal of Clinical Investigation | March 1999 | Volume 103 | Number 5
Figure 1
Targeted inactivation of 11b -HSD2 gene. (a) Structure of the targeting vec-
tor, the 11 b -HSD2 locus, and the targeted allele. (b) Southern blot
hybridization analysis of XbaI-digested genomic DNA from neomycin-
resistant nontargeted (+/+) and targeted (+/–) ES clones. (c) Northern
blot analysis of 11b -HSD2 expression. RNA (10 m g) from kidney of wild-
type (+/+), homozygous (–/–) mutants and three heterozygous (+/–) lit-
termates was hybridized with mouse 11 b -HSD2 and control (ctrl) U-1
snRNA cDNA probes. 11b -HSD2, 11b -hydroxysteroid dehydrogenase type
2; ES, embryonic stem cells.
Table 1
Concentration of electrolytes in 11b -HSD2–/– homozygous mutants, 11b -
HSD2+/– heterozygous, and 11 b -HSD2+/+ wild-type adult mice
11b -HSD2–/– 11b -HSD2–/+ 11b -HSD2+/+
n = 4 n = 4 n = 4
Plasma sodium (mmol/l) 152.1 ± 1.35 149.5 ± 0.56 150.3 ± 0.84
Plasma potassium (mmol/l) 3.2 ± 0.31A,D 4.9 ± 0.27 4.74 ± 0.2
Plasma chloride (mmol/l) 109.3 ± 1.75B,C 117.2 ± 0.86 114.7 ± 1.67
Plasma creatinine ( m mol/l) 19.1 ± 0.9 20.1 ± 0.74 19.8 ± 0.54
Plasma sodium/potassium 50.2 ± 4.60A,D 31.1 ± 1.59 32.1 ± 1.46
The concentration of electrolytes in 11b -HSD2–/– homozygous mutants, 11 b -
HSD2+/– heterozygous, and 11 b -HSD2+/+ wild-type adult mice was measured in
plasma separated from terminal cardiac blood samples of 3-month-old mice (mean
± SE). Variance was assessed by ANOVA followed by the Newman-Keuls post hoc test.
AP < 0.001, BP < 0.05 compared with 11 b -HSD2+/–.
CP < 0.05, DP < 0.001 compared with 11 b -HSD2+/+.
11b -HSD2, 11 b -hydroxysteroid dehydrogenase type 2.
To determine whether changes in renal structure were readi-
ly reversible, 3-month-old 11b -HSD2–/– mice were injected sub-
cutaneously once a day with the mineralocorticoid receptor
antagonist spironolactone (10 mg/kg, in vegetable oil) for 14
days and then sacrificed. Tissue was collected for histology.
Statistics. Data were assessed by ANOVA followed by the New-
man-Keuls post hoc test or Student’s t tests, as appropriate. Plas-
ma renin activity data were not normally distributed and were
analyzed by the Mann-Whitney test. Significance was set at P <
0.05. Values are means ± SEM.
Results
A null mutation of the 11b -HSD2 locus was generated
by replacing the genomic fragment encompassing exons
2–5 with a neomycin-resistance cassette (Fig.1a) through
homologous recombination in mouse 129 ES cells. Spe-
cific recombination was detected in 12 of 250 G418-
resistant colonies by Southern blot analysis with 5 ¢
(Fig.1b) and 3 ¢ (not shown) external probes. Three tar-
geted clones injected into blastocysts gave rise to
chimeras capable of germline transmission. Three inde-
pendent 11 b -HSD2–/– transgenic lines were established
by crossing chimeras to MF1 outbred females and sub-
sequent intercross breeding of heterozygotes.
Genotyping of 191 intercross progeny at weaning (21
days) showed clear deviation from mendelian ratios (31
–/–, 113 +/–, 47 +/+; P < 0.01), with less than half of the
expected number of 11b -HSD2–/– mice found. In contrast,
in fetuses at E18.5 ratios were close to mendelian, with 12
of 45 (26.7%) of the 11b -HSD2–/– genotype. 11b -HSD2–/–
mice appeared normal at birth, but within 48 hours
showed ~ 50% mortality. Neonatal death was usually pre-
ceded by motor weakness and reduced suckling and
accompanied by abdominal swelling with intestinal loop
dilatation. All 11b -HSD2–/– mice surviving >48 hours after
birth reached adulthood. No 11b -HSD2 mRNA was
detected in 11b -HSD2–/– mouse kidney, whereas het-
erozygotes showed a 50% reduction of 11b -HSD2 mRNA
expression (Fig 1c). Subsequently, 16% of 11b -HSD2 males
and 13% (of 75 total) females died suddenly between two
and four months of age (one 11b -HSD2–/– female died
suddenly four hours postpartum, and two died toward the
end of lactation of their first litters). In most cases (n = 6
males and 6 females) postmortem analysis revealed no
obvious cause of death (such as stroke or myocardial
infarction/rupture), though one female died with a rup-
tured aorta and pericardial bleeding, and another had
hemorrhaged around a kidney capsule. Both male and
female 11b -HSD2–/– mice surviving until adulthood were
fertile and gave rise to live homozygous offspring.
Placental NAD-dependent 11b -dehydrogenase activity
at E18.5 (full gestation at E19.5) was 13.7 ± 1.9
pmol/min/mg protein (45.5 ± 6.4% conversion) of corti-
costerone to inert 11-dehydrocorticosterone in wild-type
(+/–) 9.0 ± 0.7 pmol/ min/mg protein (30.1 ± 2.4% conver-
sion) in heterozygous (+/–) and 4.3 ± 0.6 pmol/min/mg
protein (14.4 ± 2.1%) in homozygous mutant 11b -HSD2–/–
mice (Fig. 2). Mouse placentas at E18.5 also contain 11b -
HSD type 1, an NADPH-dependent enzyme that acts as
an oxidoreductase (regenerating active glucocorticoids) in
intact cells (23). Mice homozygous for targeted disruption
of the 11b -HSD1 gene do not show alterations in plasma
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Figure 2
Variation in 11 b -HSD2 dehydrogenase and 11 b -HSD1 oxidoreductase
activities in placentas with different 11b -HSD2 genotypes. Activities (mean
± SEM) expressed as conversion of nmol [3H]-steroid substrate (either cor-
ticosterone for 11b -dehydrogenase or 11-dehydrocorticosterone for 11 b -
reductase) to pmol product/mg protein/min. (Open bars) NAD-depend-
ent 11 b -corticosterone dehydrogenase activity. (Diagonally striped bars)
NADP-dependent 11b -corticosterone dehydrogenase activity. (Horizontal-
ly striped bars) NADPH-dependent 11-dehydrocorticosterone reductase
activity. Note that activity due to 11b -HSD1 does not vary with genotype.
In contrast, NAD-dependent predominantly 11b -HSD2 activity varies with
genotype, resulting in overall NADP-preferring 11b -HSD activity in 11b -
HSD2–/– mice. The residual NAD-dependent activity in 11b -HSD2–/– pla-
centas presumably reflects activity of 11 b -HSD1 enzyme. *Significantly
greater than corresponding 11 b -HSD2–/– value (P < 0.001) and signifi-
cantly smaller than corresponding wild-type (+/+) values (P < 0.001).
NAD, nicotinamide adenine dinucleotide; NADP, nicotinamide adenine
dinucleotide phosphate.
Figure 3
Corticosterone acts as a mineralocorticoid in 11b -HSD2–/– mice. Wild-
type (open squares; n = 4) and 11b -HSD2–/– (closed squares; n = 4) mice were
injected with vehicle (days –3 to 0), followed by dexamethasone (DEX;
100 m g/kg, days 0–3) to suppress endogenous corticosterone, and final-
ly dexamethasone with replacement corticosterone (DEX + CORT; 10
mg/kg, days 3–6). Urine was collected for the last 24 h of each treatment
and electrolytes measured by automated analyzer. The abnormally low
urinary Na/K ratio in 11 b -HSD2–/– mice is reversed by dexamethasone
and recurs with corticosterone replacement, whereas the treatments
have no effect in wild-type mice. *Significantly different from corre-
sponding wild-type value (P < 0.0005).
electrolytes or blood pressure (24). 11b -HSD1 activity was
equal in placentas of all three genotypes (Fig. 2). No dif-
ferences in fetal or placental weights were found at E18.5
(fetus: homozygous mutant –/– 784 ± 16 mg, n = 11; het-
erozygous +/– 797 ± 20 mg, n = 19; wild-type +/+ 790 ± 34
mg, n = 5; placenta: –/– 142 ± 9.4 mg; +/– 147 ± 7.2 mg; +/+
152 ± 14 mg), nor were there weight differences between
genotypes (either sex) at weaning.
Adult male and female 11b -HSD2–/– mice showed
hypotonic polyuria (24-h urine volume 3.2 ± 0.3 ml vs.
2.1 ± 0.2 ml; P < 0.005), with reduced urinary concen-
trations of sodium, potassium, and creatinine (61 ±
10%, 75 ± 9%, and 71 ± 5% of wild-type, respectively; 
P < 0.001). 11b -HSD2–/– null mice had normal plasma
sodium and creatinine but showed marked
hypokalemia and hypochloremia (Table 1), with plasma
potassium levels as low as 2.4 ± 0.2 mmol/l in chroni-
cally catheterized males and 2.7 ± 0.2 mmol/l in females
(n = 3). Plasma electrolytes in heterozygotes did not dif-
fer significantly from wild-type. Eight 11 b -HSD2–/–
mice had fully suppressed plasma renin activity below
the level of detection of angiotensin I (AI)(<0.05 ng
AI/mg protein/min), whereas levels in wild-type mouse
plasma were significantly higher (0.75 ± 0.40 ng
AI/mg/min; P < 0.05, n = 8). Plasma aldosterone levels
were profoundly suppressed in 11 b -HSD2–/– male and
female mice (232 ± 93 pmol/l, n = 6) compared with
wild-type controls (3085 ± 397 pmol/l, n = 6; P < 0.0001).
To determine whether endogenous glucocorticoids
were responsible for the apparent mineralocorticoid
excess, we examined the effects on urinary Na/K ratios
of suppression of corticosterone by dexamethasone and
subsequent corticosterone replacement. Dexamethasone
reversed the low Na/K ratio in 11b -HSD2–/– mice but
had no effect in wild-type controls (Fig. 3). Replacing
corticosterone in dexamethasone-treated 11b -HSD2–/–
mice recreated low urinary Na/K ratios, whereas controls
were again unaffected.
To examine whether 11 b -HSD2 gene disruption and
the consequent apparent mineralocorticoid excess
caused hypertension, blood pressures were measured
directly in three-month-old conscious male and female
mice using chronic abdominal aortic cannulae as
described previously (19). 11b -HSD2–/– mice were
hypertensive, with mean blood pressures of 146 ± 2
mmHg in males (n = 6) and 155 ± 4 mmHg in females
(n = 3), compared with 121 ± 2 mmHg in wild-type
males (n = 4, P < 0.001) and 122 ± 3 mmHg in wild-type
females (n = 5, P < 0.05). Male heterozygotes had simi-
lar blood pressures (114 ± 4 mmHg, n = 5) to wild-type
controls. Although the three-month-old 11b -HSD2–/–
mice tended to exhibit an increased heart weight/body
weight ratio compared with age-, sex-, and weight-
matched wild-type controls (–/– 6.8 ± 0.7 mg/g, n = 6;
+/+ 5.6 ± 0.4 mg/g, n = 9; P < 0.15), the difference was
not statistically significant. Histological examination
of the hearts of 11 b -HSD2–/– mice (n = 6; 3 males and 3
females) showed no evidence of interstitial fibrosis, but
there were clear morphological features of cardiac
myocyte hypertrophy (not shown).
Three-month-old 11b -HSD2–/– mice exhibited marked
renal enlargement (353 ± 13mg, n = 6; vs. 277 ± 14 mg, n =9;
P = 0.003 in the wild-type. Histology revealed that this
increase in renal mass was the consequence of distal tubu-
lar enlargement. The glomeruli, proximal tubules,
medullary rays, medulla, and collecting ducts were all nor-
mal using the light (Fig. 4a) and electron microscopes (not
shown). However, the distal tubules showed a two- to four-
fold increase in diameter (11b -HSD2–/– mean distal tubu-
lar diameter 61.3 m m, range 42.6–96.8 m m; 11b -HSD2+/+
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Figure 4
Hyperplasia and hypertrophy of the distal renal tubular epithelium in 11b -
HSD2–/– mice. (a) In adult 11b -HSD2–/– mice, the distal tubules (d) show
considerable enlargement: the tubular diameter is increased threefold com-
pared with the distal tubule in the wild-type mice (b). Note that the proxi-
mal tubules (p) and glomeruli (g) are unaffected in the 11b -HSD2–/– mice.
(c) Hyperplasia is apparent in the 11 b -HSD2–/– mouse distal tubule (d),
which shows over 20 cells in the cross-sectional profile compared with (d)
the four to six cells observed in controls. (e) The distal tubular enlargement
(d) is evident in 11 b -HSD2–/– mice at the anatomical origin of the distal
tubule at the juxtaglomerular apparatus (j) adjacent to the glomerulus (g),
compared with (f) the nonenlarged wild-type distal tubule. md, macula
densa. (g) Proximal tubule (p) is normal in 11b -HSD2–/– kidneys. 11b -
HSD2–/– proximal tubules are indistinguishable from (h) wild-type proximal
tubules. The tubules are of similar diameter and cell number in cross sec-
tion. They are lined by cuboidal cells with granular cytoplasm and a brush
border in both animals. The same magnification was used in 11b -HSD2–/–
and corresponding wild-type control photographs. In a and b, H&E · 60; in
c and d:, H&E · 120; in e–h, H&E · 180. H&E, hematoxylin and eosin.
mean distal tubular diameter 25.7 m m, range 21.2–28.3
m m) as a result of both hyperplasia and hypertrophy of the
epithelium (Fig. 4a and c). These changes were seen at the
origin of the distal tubule at the juxtaglomerular appara-
tus and in the convoluted portion (Fig. 4e). The hypertro-
phy resulted in increased cell size, with apical displacement
of nuclei and increased granularity. Electron microscopy
revealed clear differences between the 11b -HSD2–/– ani-
mals and the wild-type controls (Fig. 5, a and b). The distal
tubular epithelial cells from 11b -HSD2–/– animals showed
an increase in size, with the subnuclear, (basal) appearing
expanded with apical displacement of the nucleus. The
11b -HSD2–/– animals showed an increase in the number of
mitochondria in each distal tubular cell, although these
remained located at the expanded basal pole. Occasional
membrane-bound enclosed vacuoles were seen in the cyto-
plasm of the distal tubular epithelial cells from the 11b -
HSD2–/– animals. All described morphological tubular
changes were identical in male and female mice.
The kidneys of gestational day 18.5 and newborn ani-
mals were histologically normal. At one week old, two
out of three of the 11 b -HSD2–/– animals showed a
minor degree of tubular dilatation, without hyperplasia
or hypertrophy, affecting <1% of tubular profiles. By
three weeks old, hypertrophy and hyperplasia of the dis-
tal tubular epithelium was evident in all of the 11 b
HSD2–/– kidneys examined.
Treatment of adult 11 b -HSD2–/– mice with spirono-
lactone for 14 days improved the hypokalemia (5.5 ± 0.6
mmol/l) but had no effect upon the histological hyper-
plasia and hypertrophy of the distal tubule.
Discussion
Targeted disruption of the 11b -HSD2 gene was success-
ful, with no 11b -HSD2 mRNA detected in the kidneys of
homozygous mutants and 50% reduction in heterozy-
gotes. Measurement of 11 b -dehydrogenase and 11 b -
reductase activities in the presence of different cofactors
and substrates in placentas also supports the absence of
11b -HSD2 activity (a high-affinity NAD-dependent 11 b -
dehydrogenase) in homozygous mutants, with approxi-
mately 50% of wild-type activity in heterozygotes.
Although the residual 11b -dehydrogenase activity with
NAD in placentas of 11b -HSD2–/– fetuses raises the pos-
sibility of a novel 11 b -HSD isoform, this seems more
likely merely to reflect 11 b -HSD1, which may continue
moderate activity without added NADP, probably due to
use of endogenous cosubstrate NADP, itself increased by
exogenous NAD (17). 11b -HSD1 activity was unaffected
by mutation of 11b -HSD2 in the placenta. The mutant
phenotype appeared to be recessive, with detectable
effects confined to homozygotes, and these findings
were in accord with the lack of apparent disorders in par-
ents or heterozygous sibs of children with SAME (25).
However, heterozygous animals have only been exam-
ined up to four months of age, and effects later in life
cannot be excluded.
Up to 50% of homozygous mice died within the first 48
hours after birth. Homozygous newborn pups in the
intercross litters appeared weaker and less successful in
competition for suckling. The abdominal swelling and
intestinal dilatation observed in some 11b -HSD2–/–
neonates before death suggests intestinal ileus. Other 11b -
HSD2–/– pups died suddenly, possibly of cardiac arrest.
Both processes are compatible with the effects of severe
hypokalemia, clearly found in surviving adult 11b -
HSD2–/– animals. The neonatal mortality mimics the doc-
umented perinatal and infant mortality of children with
SAME (25, 26). Later deaths appeared either to reflect the
hemorrhagic complications of severe hypertension or were
unexplained and referred to possible cardiac events sec-
ondary to the electrolyte disturbances.
The most obvious phenotype of 11b -HSD2–/– mice was
hypotonic polyuria, with 24-hour urine volumes
increased by 50%. Hypokalemia causes polyuria due to
nephrogenic diabetes insipidus and polydipsia in
humans (27) and presumably underlies the polyuria in
11 b -HSD2–/– mice. Hypokalemia appears secondary to
urinary losses, driven by excessive mineralocorticoid
action (low urinary Na/K ratio). In 11 b -HSD2–/– mice,
endogenous and exogenous corticosterone shows illicit
mineralocorticoid action, effects absent from wild-type
littermates. The main result of activation of mineralo-
corticoid receptors in the distal tubule is enhanced sodi-
um resorption by the epithelial cells through the epithe-
lial Na+ channel (28), which ultimately results in
elevation of blood pressure (1). Indeed, male and female
11 b -HSD2–/– animals have severe hypertension with
mean blood pressures above 145 mmHg.
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Figure 5
Electron microscopy of the distal tubular epithelial cells of 11b -HSD2–/– (a)
and wild-type controls (b). Distal tubular epithelial cells from 11b -HSD2–/–
animals show an increase in size. The subnuclear, or basal, pole is expand-
ed with apical displacement of the nucleus. The number of mitochondria
(m) in each distal tubular cell is increased, although the mitochondria
remain located at the expanded basal pole (bm, basal membrane). Occa-
sional membrane-enclosed vacuoles (v) are seen in the cytoplasm of the dis-
tal tubular epithelial cells from the 11b -HSD2–/– animals. · 3,800.
The most striking structural changes in 11b -HSD2–/–
mice are in the hyperplasia and hypertrophy confined to
the distal tubule, with the proximal tubules, loops of
Henle, and collecting ducts appearing normal. This type
of distal tubular pathology has not been reported in
other polyuric or hypokalemic syndromes that result in
marked cytoplasmic vacuolation affecting the proximal
tubules and has minor changes only in the distal tubules
with no evidence of hyperplasia or hypertrophy (29).
The changes are, however, similar to the effects of chron-
ic furosemide administration (20), in which increased
distal tubular sodium transport occurs as a consequence
of increased sodium delivery to the distal tubule after
inhibition of inward salt transport by the loop diuretic.
In 11b -HSD2–null mice, the pathology is presumably a
consequence of increased mineralocorticoid activity.
Hyperplasia of the distal tubular epithelium, with
increased total mitochondria and basal-membrane sur-
face area, would be predicted to be the consequence of
the energy requirement of overstimulation of active ion
transport by mineralocorticoid receptor activity. 11 b -
HSD2 and mineralocorticoid receptor mRNA are con-
fined to the distal nephron (30). We are not aware of any
studies of renal biopsies from patients with SAME to
allow comparison with the mice.
Kidneys from E18.5 11 b -HSD2–/– fetuses showed no
morphological or histological abnormalities. High
expression of mineralocorticoid receptor mRNA in the
distal nephron develops between E18.5 and just after
birth (at E19.5) (30). Thus, only around birth do distal
tubule epithelia of 11 b -HSD2–/– animals first become
exposed to glucocorticoid overactivation of mineralo-
corticoid receptors, findings consistent with glucocorti-
coid mediation of the distal tubular pathology. Intrigu-
ingly, in SAME patients, hypertension is usually not fully
reversed by cortisol suppression. The marked structural
abnormalities found in the adult 11 b -HSD2–/– mouse
distal tubule and the lack of reversal of these changes
with mineralocorticoid receptor antagonism in adult life
may explain this and focuses attention on renal structure
in patients with chronic steroid hypertension.
In contrast to the striking renal pathology, the
observed cardiac myocyte hypertrophy would be com-
patible with a secondary effect of hypertension alone.
The lack of cardiac fibrosis, which has been associated
with conditions of mineralocorticoid excess (not appar-
ent mineralocorticoid excess), conforms with sugges-
tions that this effect is mediated by MR unprotected by
11 b -HSD2 and therefore requires elevated plasma lev-
els of corticosteroids.
The mammalian placenta (and the fetus until midgesta-
tion) highly expresses 11b -HSD2, which may exclude high
levels of maternal glucocorticoids from fetal tissues during
sensitive periods of prenatal growth and development.
Indeed, in rats and humans, placental 11b -HSD activity
near term correlates with birth weight (31, 32) and phar-
macological inhibition of fetoplacental 11b -HSD reduces
birth weight (33). The lack of birth-weight changes in 11b -
HSD2–/– mice suggests either that there are compensatory
developmental mechanisms or, more likely, that this
species, which shows early midgestational loss of 11b -
HSD2 gene expression in the placenta and fetal tissues
(30), is less dependent on 11b -HSD2–mediated exclusion
of glucocorticoids for maintenance of birth weight, which
predominantly reflects growth in late gestation.
The 11 b -HSD2–/– mice not only model SAME and
advance our current understanding of its etiology, but
will also allow more general insights into disorders of
real or apparent mineralocorticoid excess, such as
Conn’s and Liddle’s syndromes and glucocorticoid-
remediable hyperaldosteronism (34, 2, 5), in which there
is poorly understood variation in the degree of
hypokalemia, hypertension, and the response to treat-
ment. The mice will be useful in screening for new phar-
maceutical compounds alleviating volume-dependent
hypertension and also in studies of basic molecular
mechanisms of mineralocorticoid responses in normal
and pathological states.
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